Regenerative Medicine Is Reaching the Boardroom. Here Is How Executives Should Evaluate It
By Vincent Caradec, Co-Founder & CEO, Healthi Life
A few years ago, stem cell therapy was something executives read about in science sections. Today it comes up in board dinners and founder groups, usually as a question: is it real, is it safe, and where would you even go?
Those are the right questions. The field is moving fast, the evidence is uneven, and the market includes both serious medical teams and operators who are selling hope. For a leader used to due diligence, the good news is that the same discipline you apply to an acquisition works here.
Start with what the science actually says
Regenerative medicine covers a range of approaches, from the patient's own cells to donor-derived mesenchymal stem cells (MSCs). Some uses are well established in hospital medicine. Many others, including most applications marketed for joints, skin or general vitality, are still investigational. That means clinical trials exist and some results are encouraging, but outcomes vary from person to person and nothing is guaranteed.
The International Society for Stem Cell Research (ISSCR) publishes guidelines for how cell-based treatments should be developed and offered. Reading its patient handbook takes twenty minutes and will make you a far better buyer than any brochure.
Five due-diligence questions
1. Is the facility licensed, and by whom? Ask for the medical facility licence number and check that physicians are registered with the national medical council. A legitimate provider will give you both without hesitation.
2. Who assesses you first? A physician should take a full history, review imaging or blood work, and tell you plainly if you are not a good candidate. If you can book a treatment before anyone has examined you, walk away.
3. Where do the cells come from? Ask about the laboratory, the processing standards, cell counts and viability testing, and whether the cells are fresh or frozen. Traceability matters as much in medicine as it does in your supply chain.
4. What evidence do they cite? Good teams point to published trials, explain the dose that was studied, and are honest about the limits of that evidence. Be wary of guarantees, fixed timelines or before-and-after photos presented as proof.
5. What happens after the procedure? Regenerative protocols should come with follow-up and measurement. If the relationship ends when the invoice is paid, nobody is tracking whether it worked or whether anything went wrong.
Why Asia is part of the conversation
Many executives look to Asia because the region combines strong private hospitals, specialist laboratories and physicians trained in Europe, the US and locally. Bangkok in particular has become a destination for international patients who want medical quality with shorter waiting times.
Geography is not a quality signal on its own, though. The five questions above apply in Bangkok, Singapore, Zurich or Miami. The best providers welcome them.
What a sensible first step looks like
For most executives, the right first step is not a procedure. It is a proper baseline: blood work, imaging where relevant, and an honest conversation about goals, timelines and risks. That baseline gives you something to measure against later, and it often shows that the problem you wanted to fix has a simpler cause, such as sleep, inflammation or a nutrient deficiency. Treat it the way you would treat a pilot project before a large investment: small, measured and reviewed before you commit further.
Regeneration belongs inside a longer plan
The most useful shift I have seen is moving from one-off procedures to a measured plan. At Healthi Life, our longevity house in Bangkok, every guest starts with an advanced health check-up read by a physician. Regenerative protocols, when they are appropriate, sit at the end of a sequence we describe as Repair, Recover, Regenerate, and they are reviewed with repeat measurement, with physician follow-up within 30 to 90 days and then quarterly. Sometimes the right answer after testing is that a guest does not need cell therapy at all.
If you want to see how a physician-led approach is structured, including published prices and the research behind it, our page on physician-led stem cell therapy in Bangkok sets it out.
Leaders spend years managing risk on behalf of their companies. Applying the same rigor to your own health is not a luxury. It is part of the job.
This article is general information, not medical advice. Stem cell and other regenerative treatments are provided only after a medical consultation and a physician's assessment; many applications remain investigational and results vary from person to person. Healthi Life is licensed as Healthi-Life Medical Clinic (licence 10101003468), with physicians licensed by the Thai Medical Council.
